Key Performance
More- Earnings Score: N/A
- Momentum Score: 45
- True Yield: N/A
- Financial Health Score: N/A
%20scale(1,1)}%2025%25%20{transform:%20translate(24.943161px,19.954806px)%20scale(0.85,0.85)}%2050%25%20{transform:%20translate(24.943161px,19.954806px)%20scale(0.7,0.7)}%2075%25%20{transform:%20translate(24.943161px,19.954806px)%20scale(0.85,0.85)}%20100%25%20{transform:%20translate(24.943161px,19.954806px)%20scale(1,1)}}%20%23ewMkZ6d8Hun3_ts%20{animation:%20ewMkZ6d8Hun3_ts__ts%204000ms%20linear%20infinite%20normal%20forwards}@keyframes%20ewMkZ6d8Hun3_ts__ts%20{%200%25%20{transform:%20translate(24.9787px,20.012362px)%20scale(1,1)}%2025%25%20{transform:%20translate(24.9787px,20.012362px)%20scale(0.85,0.85)}%2050%25%20{transform:%20translate(24.9787px,20.012362px)%20scale(0.7,0.7)}%2075%25%20{transform:%20translate(24.9787px,20.012362px)%20scale(0.85,0.85)}%20100%25%20{transform:%20translate(24.9787px,20.012362px)%20scale(1,1)}}%20]]%3e%3c/style%3e%3cdefs%3e%3clinearGradient%20id='ewMkZ6d8Hun2-fill'%20x1='12.5'%20y1='23.5001'%20x2='-0.868518'%20y2='16.4047'%20spreadMethod='pad'%20gradientUnits='userSpaceOnUse'%20gradientTransform='translate(0%200)'%3e%3cstop%20id='ewMkZ6d8Hun2-fill-0'%20offset='0%25'%20stop-color='%23FF2F00'/%3e%3cstop%20id='ewMkZ6d8Hun2-fill-1'%20offset='100%25'%20stop-color='%23FF9100'/%3e%3c/linearGradient%3e%3clinearGradient%20id='ewMkZ6d8Hun3-fill'%20x1='31.5059'%20y1='27.1026'%20x2='10.2884'%20y2='14.9373'%20spreadMethod='pad'%20gradientUnits='userSpaceOnUse'%20gradientTransform='translate(0%200)'%3e%3cstop%20id='ewMkZ6d8Hun3-fill-0'%20offset='4.7%25'%20stop-color='%23FF2F00'/%3e%3cstop%20id='ewMkZ6d8Hun3-fill-1'%20offset='100%25'%20stop-color='%23FF9100'/%3e%3c/linearGradient%3e%3c/defs%3e%3cg%20id='ewMkZ6d8Hun2_ts'%20transform='translate(24.943161,19.954806)%20scale(1,1)'%3e%3cpath%20d='M14.8466,29.2814c0,0-14.408088-4.6983-12.05895-19.79995c0,0,1.50345,4.85085,4.13448,5.30845s-2.03592,4.6373,7.92447,14.4915Z'%20transform='translate(-24.943161,-19.954806)'%20fill='url(%23ewMkZ6d8Hun2-fill)'/%3e%3c/g%3e%3cg%20id='ewMkZ6d8Hun3_ts'%20transform='translate(24.9787,20.012362)%20scale(1,1)'%3e%3cpath%20d='M37.4922,21.9282l4.0719.244v-12.81353C31.0713,3.28748,17.7595,7.6502,17.7595,7.6502c.3445-4.51526-3.5707-5.52204-3.5707-5.52204c2.5371,1.52542.3132,6.22373.3132,6.22373C13.0299,0.084092,0,1.02986,0,1.02986C8.92672,4.35528,6.70287,7.98579,6.8908,16.6197c.18794,8.6034,8.3943,12.9966,8.3943,12.9966l-6.60895-.2441v13.2407c0,0,5.48135,2.3797,13.68765,3.1729v-22.3017h-4.4477c-1.0023,0-1.942-.8237-1.942-1.8v-5.7356c0-.9763.9397-1.8,1.942-1.8h4.4477v-1.3424h5.0115v1.3424h5.0115c1.0023,0,1.848.7932,1.848,1.8v5.7356c0,.9763-.8144,1.8-1.848,1.8h-5.0115v22.5153h.2819c11.1192-.0611,15.9428-7.3221,16.256-13.3017.4698-7.7492-6.421-10.7695-6.421-10.7695Z'%20transform='translate(-24.9787,-20.012361)'%20fill='url(%23ewMkZ6d8Hun3-fill)'/%3e%3c/g%3e%3c/svg%3e)
Latest Research & News
Kuehn Law Encourages Investors of Vistagen Therapeutics, Inc. to Contact Law Firm
Kuehn Law is investigating whether officers and directors of Vistagen Therapeutics breached fiduciary duties by misrepresenting or failing to disclose risks in their Social Anxiety Disorder clinical trials. The firm alleges insiders downplayed known issues with public speaking challenge endpoints, including elevated placebo responses and site variability, while promoting the PALISADE-3 trial as likely to succeed. The law firm is seeking shareholders who purchased stock prior to April 1, 2024.
06/01/2026, 2:40 PM • Benzinga
A securities class action lawsuit has been filed against Vistagen Therapeutics, Inc. (NASDAQ: VTGN) alleging that defendants made materially false and misleading statements regarding the company's drug fasedienol and its Phase 3 PALISADE-3 clinical trial. Investors who purchased VTGN stock between April 1, 2024 and December 16, 2025 may be eligible for compensation. The deadline to serve as lead plaintiff is March 16, 2026.
03/14/2026, 6:01 PM • GlobeNewswire
A class action lawsuit has been filed against Vistagen Therapeutics for alleged securities fraud, claiming the company made materially false and misleading statements about its fasedienol drug candidate and the PALISADE-3 clinical trial while concealing adverse data. Investors who purchased Vistagen securities between April 1, 2024 and December 16, 2025 may be eligible to join the case, with a lead plaintiff deadline of March 16, 2026.
03/12/2026, 12:00 PM • GlobeNewswire
The Schall Law Firm is seeking investors who purchased Vistagen Therapeutics securities between April 1, 2024 and December 16, 2025 to join a class action lawsuit alleging securities fraud. The company allegedly made false and misleading statements about its fasedienol drug candidate's Phase 3 success potential in the PALISADE-2 trial and downplayed clinical failure risks, resulting in investor losses.
03/09/2026, 10:00 AM • GlobeNewswire
Rosen Law Firm is notifying investors in Vistagen Therapeutics who purchased stock between April 1, 2024 and December 16, 2025 of a March 16, 2026 deadline to join a securities class action lawsuit. The lawsuit alleges that Vistagen made false and misleading statements about its drug fasedienol and the PALISADE-3 clinical trial, providing overly positive assertions while concealing material adverse facts about the Phase 3 trial.
03/07/2026, 9:14 AM • GlobeNewswire
A class action lawsuit has been filed against Vistagen Therapeutics for alleged securities fraud. The complaint alleges that the company made materially false and misleading statements regarding its fasedienol drug candidate and the Phase 3 PALISADE-3 trial for social anxiety disorder treatment, while concealing adverse clinical data. Investors who purchased Vistagen securities between April 1, 2024 and December 16, 2025 may be eligible to join the case.
03/05/2026, 12:00 PM • GlobeNewswire
A securities class action lawsuit has been filed against Vistagen Therapeutics regarding alleged material misstatements and omissions concerning its fasedienol drug trial (PALISADE-3) for social anxiety disorder. The company allegedly made positive assertions about the drug's future success while concealing adverse facts about the Phase 3 trial. Investors who purchased stock between April 1, 2024 and December 16, 2025 may be eligible for compensation, with a March 16, 2026 deadline to serve as lead plaintiff.
03/04/2026, 10:20 PM • GlobeNewswire
A class action lawsuit has been filed against Vistagen Therapeutics for allegedly providing misleading statements regarding its Phase 3 PALISADE-3 trial of fasedienol for social anxiety disorder. The trial failed to meet its primary endpoint, causing Vistagen's stock to plummet over 80% from $4.36 to $0.86 per share on December 17, 2025. Investors who purchased shares between April 1, 2024 and December 16, 2025 have until March 16, 2026 to apply as lead plaintiff.
03/04/2026, 8:16 PM • GlobeNewswire
Rosen Law Firm announces a March 16, 2026 deadline for investors to join a securities class action lawsuit against Vistagen Therapeutics, Inc. (VTGN). The lawsuit alleges that company defendants made misleading positive statements about the fasedienol drug trial (PALISADE-3) for acute social anxiety disorder treatment while concealing material negative facts, causing shareholders to purchase stock at artificially inflated prices.
03/01/2026, 7:53 PM • GlobeNewswire
A securities class action lawsuit has been filed against Vistagen Therapeutics regarding alleged material misstatements about its fasedienol drug development for social anxiety disorder. Investors who purchased VTGN stock between April 1, 2024 and December 16, 2025 may be eligible for compensation. The lead plaintiff deadline is March 16, 2026.
03/01/2026, 7:53 PM • GlobeNewswire
Holzer & Holzer, LLC announces lead plaintiff deadlines for shareholder class action lawsuits against CoreWeave, Bath & Body Works, and Vistagen Therapeutics. The lawsuits allege materially false statements regarding CoreWeave's ability to meet customer demand, Bath & Body Works's customer growth and net sales, and Vistagen's Phase 3 trial risks. Investors who purchased shares during specified periods and suffered losses are encouraged to seek lead plaintiff status by March 13-16, 2026.
02/26/2026, 12:49 PM • GlobeNewswire
Pomerantz Law Firm has filed a class action lawsuit against Vistagen Therapeutics following the failure of its PALISADE-3 Phase 3 clinical trial for intranasal fasedienol in treating social anxiety disorder. The trial did not meet its primary endpoint, resulting in an 80.25% stock price decline on December 17, 2025. Investors with losses are urged to contact the firm by the March 16, 2026 deadline to potentially become lead plaintiffs.
02/24/2026, 3:51 PM • GlobeNewswire
Shareholder class action lawsuits have been filed against Vistagen Therapeutics, Varonis Systems, and Kyndryl Holdings, alleging false and misleading statements or failure to disclose material risks. Investors who suffered losses during specified periods are encouraged to contact the law firm, with lead plaintiff deadlines ranging from March 9 to April 13, 2026.
02/24/2026, 8:00 AM • GlobeNewswire
A securities class action lawsuit has been filed against Vistagen Therapeutics for allegedly providing investors with misleading positive statements about its fasedienol drug trial (PALISADE-3) while concealing material adverse facts. Investors who purchased VTGN stock between April 1, 2024 and December 16, 2025 may be eligible for compensation. The lead plaintiff deadline is March 16, 2026.
02/23/2026, 5:46 PM • GlobeNewswire
A class action lawsuit has been filed against Vistagen Therapeutics, Inc. alleging that the company made materially false and misleading statements regarding its fasedienol drug candidate and the PALISADE-3 clinical trial. The lawsuit covers investors who purchased Vistagen securities between April 1, 2024 and December 16, 2025. The lead plaintiff deadline is March 16, 2026.
02/23/2026, 12:00 PM • GlobeNewswire
Peers
Statistics
MoreInformation as of 06/03/2026
Company Profile
Vistagen Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development and commercialization of therapies for neuropsychiatric and neurological disorders. The company's product pipeline includes Fasedienol, an investigational pherine nasal spray that is in Phase III clinical trial for the treatment of anxiety in adults with social anxiety disorder; and Itruvone, an odorless synthetic investigational neuroactive pherine nasal spray, which is in Phase II clinical trial to treat major depressive disorder. It also develops PH80, an odorless and tasteless synthetic investigational pherine nasal spray that is in Phase II clinical trial for the treatment of vasomotor symptoms, including hot flashes due to menopause, premenstrual dysphoric disorder, and other women's health disorders; PH15, an investigational pherine nasal spray, which is in Phase II clinical trial for the treatment to improve cognitive impairment caused by mental fatigue and potentially other disorders; PH284, an odorless and tasteless synthetic investigational pherine nasal spray that is in Phase II clinical trial to treat loss of appetite associated with chronic disorders, such as cancer or heart disease, as well as cachexia; and AV-101, an oral prodrug that targets N-methyl-D-aspartate receptor in the brain for treating depression and neurological disorders. In addition, the company's clinical-stage pipeline consists of intranasal product candidates comprising pherines. It has a license and collaboration agreement with AffaMed Therapeutics, Inc. to develop, manufacture, and commercialize fasedienol for multiple anxiety-related disorders. Vistagen Therapeutics, Inc. was founded in 1998 and is headquartered in South San Francisco, California.